Form 4 Filing for Nicholas Conrad Smith

Nicholas Conrad Smith, President and CFO of Alto Neuroscience, Inc., reported a transaction on October 2, 2026. He acquired 55,000 shares of Common Stock at a price of $2.32 per share, bringing his post-transaction total to 79,060 shares. Additionally, Smith exercised an employee stock option for 55,000 shares of Common Stock, with a strike price of $2.32. The shares underlying this option vest over time, with 25% vesting on September 8, 2022, and the remainder vesting monthly over 48 months, contingent upon continued service. Following this exercise, Smith holds 57,405 shares underlying options. This filing is classified as an OFFICER_DIRECTOR_CHANGE due to the reporting of stock transactions by a corporate officer.